leadf
logo-loader
viewArecor

Arecor extends collaboration with top five pharmaceutical firm for new medicine formula

Under the deal, the pharma firm will fund a feasibility study into a liquid formulation of a ready-to-administer medicine using Arecor's Arestat technology

Arecor - Arecor extends collaboration with top five pharmaceutical firm for new medicine formula

Arecor Ltd has inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.

The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.

READ: Arecor signs agreement with Hikma Pharma to develop new injectable medicine

"This is the second RTA collaboration that we have announced in recent weeks involving our proprietary technology platform Arestat. It is a further project for an existing pharmaceutical partner which demonstrates the value of our technology and expertise together with the strength of our commercial relationships”, said Arecor chief executive Sarah Howell.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

2 days, 10 hours ago

2 min read